Amneal Pharmaceuticals (Germany) Performance
| 2DT Stock | EUR 7.30 0.25 3.31% |
The firm shows a Beta (market volatility) of 0.71, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Amneal Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Amneal Pharmaceuticals is expected to be smaller as well. Amneal Pharmaceuticals right now shows a risk of 3.1%. Please confirm Amneal Pharmaceuticals downside deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if Amneal Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Weak
Over the last 90 days Amneal Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Amneal Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 347.1 M | |
| Total Cashflows From Investing Activities | -194.2 M |
Amneal |
Amneal Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 745.00 in Amneal Pharmaceuticals on September 21, 2024 and sell it today you would lose (15.00) from holding Amneal Pharmaceuticals or give up 2.01% of portfolio value over 90 days. Amneal Pharmaceuticals is currently producing 0.0153% returns and takes up 3.0958% volatility of returns over 90 trading days. Put another way, 27% of traded stocks are less volatile than Amneal, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Amneal Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amneal Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Amneal Pharmaceuticals, and traders can use it to determine the average amount a Amneal Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0049
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 2DT |
Estimated Market Risk
| 3.1 actual daily | 27 73% of assets are more volatile |
Expected Return
| 0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Amneal Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Amneal Pharmaceuticals by adding Amneal Pharmaceuticals to a well-diversified portfolio.
Amneal Pharmaceuticals Fundamentals Growth
Amneal Stock prices reflect investors' perceptions of the future prospects and financial health of Amneal Pharmaceuticals, and Amneal Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Amneal Stock performance.
| Return On Equity | -0.88 | |||
| Return On Asset | 0.0257 | |||
| Profit Margin | (0.06) % | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | 2.95 B | |||
| Shares Outstanding | 151.48 M | |||
| Price To Earning | 8.70 X | |||
| Price To Book | 1.17 X | |||
| Price To Sales | 0.29 X | |||
| Revenue | 2.09 B | |||
| EBITDA | 401.1 M | |||
| Cash And Equivalents | 452.1 M | |||
| Cash Per Share | 3.04 X | |||
| Total Debt | 2.72 B | |||
| Debt To Equity | 7.78 % | |||
| Book Value Per Share | 1.96 X | |||
| Cash Flow From Operations | 241.82 M | |||
| Earnings Per Share | (0.73) X | |||
| Total Asset | 3.94 B | |||
About Amneal Pharmaceuticals Performance
By analyzing Amneal Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Amneal Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Amneal Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Amneal Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey. AMNEAL PHMCTCLS operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 6000 people.Things to note about Amneal Pharmaceuticals performance evaluation
Checking the ongoing alerts about Amneal Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Amneal Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Amneal Pharmaceuticals had very high historical volatility over the last 90 days | |
| Amneal Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| About 68.0% of the company shares are owned by institutions such as pension funds |
- Analyzing Amneal Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Amneal Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Amneal Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Amneal Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Amneal Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Amneal Pharmaceuticals' stock. These opinions can provide insight into Amneal Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Amneal Stock analysis
When running Amneal Pharmaceuticals' price analysis, check to measure Amneal Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals is operating at the current time. Most of Amneal Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals' price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |